Home > Press Releases > Oral Biologics Market

Oral Biologics Market Likely to Surpass USD 16.9 Billion by 2035

Report Code: HC-9879  |  Published in: Sep 2026, By MarketGenics  |  Number of pages: 336
Get PDF
Buy

Global Oral Biologics Market Forecast 2035:

According to the report, the global oral biologics market is projected to expand from USD 3.7 billion in 2025 to USD 16.9 billion by 2035, registering a CAGR of 16.4%, the highest during the forecast period. The rising demand for noninjectable therapies, growth of oral delivery technologies, and increased investment in peptide and protein drugs are key factors driving the growth of the oral biologics market.

Pharmaceutical companies are working on technologies to make biologics resistant to degradation in the gastrointestinal tract and enhance their systemic absorption, which will have a wider therapeutic use. For instance, in February 2025, Oramed partnered with Hefei Tianhui Biotech to collaborate on advancing its oral insulin development program, with Hefei providing specialized manufacturing expertise and Oramed contributing a $75 million investment.

In addition, robust clinical-development infrastructure exists with ACRO members conducting 7,634 studies by end-2025 involving 1.4 million patients, providing an excellent platform for the development of innovative biologic treatments. The rapid growth of delivery technologies, manufacturing capacity, and clinical development infrastructure is driving the commercialization and extension of the uses of oral biologics                         

Key Driver, Restraint, and Growth Opportunity Shaping the Global Oral Biologics Market

New developments in oral drug delivery systems are increasing the potential for delivery of complex biologics via nonparenteral routes. The innovative capsule-based and device-enabled systems are engineered to address gastrointestinal barriers, improve systemic drug absorption and provide more stable drug levels, which will help to increase the use of oral biologic therapies.                  

Oral biologics require sophisticated formulations, specialized excipients, advanced delivery technologies, and stringent manufacturing controls to maintain molecular stability and therapeutic performance. These requirements increase development complexity, production costs, and technical risks compared with conventional injectable biologics, potentially limiting adoption among manufacturers.                             

Innovative excipient technologies provide substantial prospects to increase the solubility, gastrointestinal stability, permeability, and systemic absorption of oral biologicals. The combination of new excipients and sophisticated formulation methodologies can improve bioavailability, maximize dosage efficiency, and facilitate the development of diverse oral formulations for a variety of therapeutic purposes.             

Expansion of Global Oral Biologics Market

Shift Toward Food-Independent Oral Biologic Formulations

  • The oral biologics market is moving toward formulations that reduce or eliminate food/fasting restriction, making it easier to administer and easier for patients to take. The advent of small-molecule and advanced oral delivery technologies is helping manufacturers create therapeutics that can be administered with less administration.
  • For instance, in June 2026, Eli Lilly announced that its once-daily oral GLP-1 drug, Foundayo (orforglipron), could be administered without food and water restrictions and showed impressive weight loss results in menopausal populations. The move is emblematic of the industry's shift toward more patient-friendly, oral treatments.
  • The convenience and commercial value of oral therapies are enhanced by a food-independent dosing option.

Regional Analysis of Global Oral Biologics Market

  • North America has the highest demand as it has a mature biopharmaceutical ecosystem, significant R&D investments, advanced clinical facilities, and robust commercialization potential. For instance, in July 2026, Rani Therapeutics reported Phase 1a results for oral RT-114, demonstrating more than 150% systemic exposure compared with matched subcutaneous PG-102, highlighting the region’s advanced oral delivery capabilities. The innovation capabilities and quick clinical translation are further strengthening North America's leadership as a demand region.
  • Asia Pacific is experiencing strong growth supported by expanding biopharmaceutical manufacturing, increasing healthcare investment, improving clinical-development capabilities, and rising demand for advanced therapies. For instance, in August 2026, Thermo Fisher Scientific indicated continued double-digit growth expectations in India, driven by expanding biopharmaceutical research and manufacturing activities, highlighting strengthening regional infrastructure.       

Prominent players operating in the global oral biologics market is AstraZeneca plc, Biocon Limited, Chugai Pharmaceutical, Cyclo Therapeutics, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Entera Bio Ltd., Innovent Biologics, Inc., Merck & Co., Novo Nordisk, Oramed Pharmaceuticals, Pfizer Inc., Protagonist Therapeutics Inc., Rani Therapeutics Holdings, Inc., Sanofi S.A., Sun Pharmaceutical Industries, Others.      

The global oral biologics market has been segmented as follows:

Global Oral Biologics Market Analysis, By Molecule Type

  • Peptides
  • Proteins & Enzymes
  • Vaccines (Oral)
  • Hormones
  • Nucleic Acid-based Biologics
  • Live Biotherapeutic Products
  • Other Types

Global Oral Biologics Market Analysis, By Delivery Technology

  • Permeation Enhancer-based Systems
  • Enteric Coating Technologies
  • Lipid-based Nanocarriers
  • Polymer-based Nanoparticle Carriers
  • Micro-injector Oral Devices
  • Hydrogel & Mucoadhesive Systems
  • Protease Inhibitor-based Formulations
  • Cell-penetrating Peptide Conjugates
  • Other Technologies

Global Oral Biologics Market Analysis, By Dosage Form

  • Tablets
  • Capsules
  • Oral Films
  • Oral Suspensions
  • Powders for Reconstitution

Global Oral Biologics Market Analysis, By Therapeutic Area

  • Diabetes (Oral Insulin, GLP-1 analogs)
  • Autoimmune & Inflammatory Diseases
  • Gastrointestinal Disorders
  • Oncology
  • Infectious Diseases
  • Hormonal/Endocrine Disorders
  • Cardiovascular Diseases
  • Osteoporosis & Bone Disorders
  • Others

Global Oral Biologics Market Analysis, By Indication

  • Chronic Disease Management
  • Acute Care
  • Preventive/Prophylactic Use

Global Oral Biologics Market Analysis, By End User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Academic & Research Institutes
  • CROs/ CDMOs

Global Oral Biologics Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America 

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Oral Biologics Market Outlook
      • 2.1.1. Oral Biologics Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Rising preference for convenient, needle-free administration of biologic therapies
        • 4.1.1.2. Advances in drug delivery technologies improve oral biologic absorption
        • 4.1.1.3. Growing development of oral peptide and protein therapies expands opportunities
      • 4.1.2. Restraints
        • 4.1.2.1. Gastrointestinal degradation limits oral bioavailability of biologic drugs.
        • 4.1.2.2. Complex formulations increase development costs and regulatory challenges
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Oral Biologics Market Demand
      • 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Oral Biologics Market Analysis, by Molecule Type
    • 6.1. Key Segment Analysis
    • 6.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Molecule Type, 2021-2035
      • 6.2.1. Peptides
      • 6.2.2. Proteins & Enzymes
      • 6.2.3. Vaccines (Oral)
      • 6.2.4. Hormones
      • 6.2.5. Nucleic Acid-based Biologics
      • 6.2.6. Live Biotherapeutic Products
      • 6.2.7. Other Types
  • 7. Global Oral Biologics Market Analysis, by Delivery Technology
    • 7.1. Key Segment Analysis
    • 7.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Delivery Technology, 2021-2035
      • 7.2.1. Permeation Enhancer-based Systems
      • 7.2.2. Enteric Coating Technologies
      • 7.2.3. Lipid-based Nanocarriers
      • 7.2.4. Polymer-based Nanoparticle Carriers
      • 7.2.5. Micro-injector Oral Devices
      • 7.2.6. Hydrogel & Mucoadhesive Systems
      • 7.2.7. Protease Inhibitor-based Formulations
      • 7.2.8. Cell-penetrating Peptide Conjugates
      • 7.2.9. Other Technologies
  • 8. Global Oral Biologics Market Analysis, by Dosage Form
    • 8.1. Key Segment Analysis
    • 8.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Dosage Form, 2021-2035
      • 8.2.1. Tablets
      • 8.2.2. Capsules
      • 8.2.3. Oral Films
      • 8.2.4. Oral Suspensions
      • 8.2.5. Powders for Reconstitution
  • 9. Global Oral Biologics Market Analysis, by Therapeutic Area
    • 9.1. Key Segment Analysis
    • 9.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Area, 2021-2035
      • 9.2.1. Diabetes (Oral Insulin, GLP-1 analogs)
      • 9.2.2. Autoimmune & Inflammatory Diseases
      • 9.2.3. Gastrointestinal Disorders
      • 9.2.4. Oncology
      • 9.2.5. Infectious Diseases
      • 9.2.6. Hormonal/Endocrine Disorders
      • 9.2.7. Cardiovascular Diseases
      • 9.2.8. Osteoporosis & Bone Disorders
      • 9.2.9. Others
  • 10. Global Oral Biologics Market Analysis, by Indication
    • 10.1. Key Segment Analysis
    • 10.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Indication, 2021-2035
      • 10.2.1. Chronic Disease Management
      • 10.2.2. Acute Care
      • 10.2.3. Preventive/Prophylactic Use
  • 11. Global Oral Biologics Market Analysis, by End User
    • 11.1. Key Segment Analysis
    • 11.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
      • 11.2.1. Hospitals
      • 11.2.2. Specialty Clinics
      • 11.2.3. Homecare Settings
      • 11.2.4. Academic & Research Institutes
      • 11.2.5. CROs/ CDMOs
  • 12. Global Oral Biologics Market Analysis, by Region
    • 12.1. Key Findings
    • 12.2. Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 12.2.1. North America
      • 12.2.2. Europe
      • 12.2.3. Asia Pacific
      • 12.2.4. Middle East
      • 12.2.5. Africa
      • 12.2.6. South America
  • 13. North America Oral Biologics Market Analysis
    • 13.1. Key Segment Analysis
    • 13.2. Regional Snapshot
    • 13.3. North America Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 13.3.1. Molecule Type
      • 13.3.2. Delivery Technology
      • 13.3.3. Dosage Form
      • 13.3.4. Therapeutic Area
      • 13.3.5. Indication
      • 13.3.6. End User
      • 13.3.7. Country
        • 13.3.7.1. USA
        • 13.3.7.2. Canada
        • 13.3.7.3. Mexico
    • 13.4. USA Oral Biologics Market
      • 13.4.1. Country Segmental Analysis
      • 13.4.2. Molecule Type
      • 13.4.3. Delivery Technology
      • 13.4.4. Dosage Form
      • 13.4.5. Therapeutic Area
      • 13.4.6. Indication
      • 13.4.7. End User
    • 13.5. Canada Oral Biologics Market
      • 13.5.1. Country Segmental Analysis
      • 13.5.2. Molecule Type
      • 13.5.3. Delivery Technology
      • 13.5.4. Dosage Form
      • 13.5.5. Therapeutic Area
      • 13.5.6. Indication
      • 13.5.7. End User
    • 13.6. Mexico Oral Biologics Market
      • 13.6.1. Country Segmental Analysis
      • 13.6.2. Molecule Type
      • 13.6.3. Delivery Technology
      • 13.6.4. Dosage Form
      • 13.6.5. Therapeutic Area
      • 13.6.6. Indication
      • 13.6.7. End User
  • 14. Europe Oral Biologics Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. Europe Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Molecule Type
      • 14.3.2. Delivery Technology
      • 14.3.3. Dosage Form
      • 14.3.4. Therapeutic Area
      • 14.3.5. Indication
      • 14.3.6. End User
      • 14.3.7. Country
        • 14.3.7.1. Germany
        • 14.3.7.2. United Kingdom
        • 14.3.7.3. France
        • 14.3.7.4. Italy
        • 14.3.7.5. Spain
        • 14.3.7.6. Netherlands
        • 14.3.7.7. Nordic Countries
        • 14.3.7.8. Poland
        • 14.3.7.9. Russia & CIS
        • 14.3.7.10. Rest of Europe
    • 14.4. Germany Oral Biologics Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Molecule Type
      • 14.4.3. Delivery Technology
      • 14.4.4. Dosage Form
      • 14.4.5. Therapeutic Area
      • 14.4.6. Indication
      • 14.4.7. End User
    • 14.5. United Kingdom Oral Biologics Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Molecule Type
      • 14.5.3. Delivery Technology
      • 14.5.4. Dosage Form
      • 14.5.5. Therapeutic Area
      • 14.5.6. Indication
      • 14.5.7. End User
    • 14.6. France Oral Biologics Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Molecule Type
      • 14.6.3. Delivery Technology
      • 14.6.4. Dosage Form
      • 14.6.5. Therapeutic Area
      • 14.6.6. Indication
      • 14.6.7. End User
    • 14.7. Italy Oral Biologics Market
      • 14.7.1. Country Segmental Analysis
      • 14.7.2. Molecule Type
      • 14.7.3. Delivery Technology
      • 14.7.4. Dosage Form
      • 14.7.5. Therapeutic Area
      • 14.7.6. Indication
      • 14.7.7. End User
    • 14.8. Spain Oral Biologics Market
      • 14.8.1. Country Segmental Analysis
      • 14.8.2. Molecule Type
      • 14.8.3. Delivery Technology
      • 14.8.4. Dosage Form
      • 14.8.5. Therapeutic Area
      • 14.8.6. Indication
      • 14.8.7. End User
    • 14.9. Netherlands Oral Biologics Market
      • 14.9.1. Country Segmental Analysis
      • 14.9.2. Molecule Type
      • 14.9.3. Delivery Technology
      • 14.9.4. Dosage Form
      • 14.9.5. Therapeutic Area
      • 14.9.6. Indication
      • 14.9.7. End User
    • 14.10. Nordic Countries Oral Biologics Market
      • 14.10.1. Country Segmental Analysis
      • 14.10.2. Molecule Type
      • 14.10.3. Delivery Technology
      • 14.10.4. Dosage Form
      • 14.10.5. Therapeutic Area
      • 14.10.6. Indication
      • 14.10.7. End User
    • 14.11. Poland Oral Biologics Market
      • 14.11.1. Country Segmental Analysis
      • 14.11.2. Molecule Type
      • 14.11.3. Delivery Technology
      • 14.11.4. Dosage Form
      • 14.11.5. Therapeutic Area
      • 14.11.6. Indication
      • 14.11.7. End User
    • 14.12. Russia & CIS Oral Biologics Market
      • 14.12.1. Country Segmental Analysis
      • 14.12.2. Molecule Type
      • 14.12.3. Delivery Technology
      • 14.12.4. Dosage Form
      • 14.12.5. Therapeutic Area
      • 14.12.6. Indication
      • 14.12.7. End User
    • 14.13. Rest of Europe Oral Biologics Market
      • 14.13.1. Country Segmental Analysis
      • 14.13.2. Molecule Type
      • 14.13.3. Delivery Technology
      • 14.13.4. Dosage Form
      • 14.13.5. Therapeutic Area
      • 14.13.6. Indication
      • 14.13.7. End User
  • 15. Asia Pacific Oral Biologics Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Asia Pacific Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Molecule Type
      • 15.3.2. Delivery Technology
      • 15.3.3. Dosage Form
      • 15.3.4. Therapeutic Area
      • 15.3.5. Indication
      • 15.3.6. End User
      • 15.3.7. Country
        • 15.3.7.1. China
        • 15.3.7.2. India
        • 15.3.7.3. Japan
        • 15.3.7.4. South Korea
        • 15.3.7.5. Australia and New Zealand
        • 15.3.7.6. Indonesia
        • 15.3.7.7. Malaysia
        • 15.3.7.8. Thailand
        • 15.3.7.9. Vietnam
        • 15.3.7.10. Rest of Asia Pacific
    • 15.4. China Oral Biologics Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Molecule Type
      • 15.4.3. Delivery Technology
      • 15.4.4. Dosage Form
      • 15.4.5. Therapeutic Area
      • 15.4.6. Indication
      • 15.4.7. End User
    • 15.5. India Oral Biologics Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Molecule Type
      • 15.5.3. Delivery Technology
      • 15.5.4. Dosage Form
      • 15.5.5. Therapeutic Area
      • 15.5.6. Indication
      • 15.5.7. End User
    • 15.6. Japan Oral Biologics Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Molecule Type
      • 15.6.3. Delivery Technology
      • 15.6.4. Dosage Form
      • 15.6.5. Therapeutic Area
      • 15.6.6. Indication
      • 15.6.7. End User
    • 15.7. South Korea Oral Biologics Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Molecule Type
      • 15.7.3. Delivery Technology
      • 15.7.4. Dosage Form
      • 15.7.5. Therapeutic Area
      • 15.7.6. Indication
      • 15.7.7. End User
    • 15.8. Australia and New Zealand Oral Biologics Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Molecule Type
      • 15.8.3. Delivery Technology
      • 15.8.4. Dosage Form
      • 15.8.5. Therapeutic Area
      • 15.8.6. Indication
      • 15.8.7. End User
    • 15.9. Indonesia Oral Biologics Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Molecule Type
      • 15.9.3. Delivery Technology
      • 15.9.4. Dosage Form
      • 15.9.5. Therapeutic Area
      • 15.9.6. Indication
      • 15.9.7. End User
    • 15.10. Malaysia Oral Biologics Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Molecule Type
      • 15.10.3. Delivery Technology
      • 15.10.4. Dosage Form
      • 15.10.5. Therapeutic Area
      • 15.10.6. Indication
      • 15.10.7. End User
    • 15.11. Thailand Oral Biologics Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Molecule Type
      • 15.11.3. Delivery Technology
      • 15.11.4. Dosage Form
      • 15.11.5. Therapeutic Area
      • 15.11.6. Indication
      • 15.11.7. End User
    • 15.12. Vietnam Oral Biologics Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Molecule Type
      • 15.12.3. Delivery Technology
      • 15.12.4. Dosage Form
      • 15.12.5. Therapeutic Area
      • 15.12.6. Indication
      • 15.12.7. End User
    • 15.13. Rest of Asia Pacific Oral Biologics Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Molecule Type
      • 15.13.3. Delivery Technology
      • 15.13.4. Dosage Form
      • 15.13.5. Therapeutic Area
      • 15.13.6. Indication
      • 15.13.7. End User
  • 16. Middle East Oral Biologics Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Middle East Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Molecule Type
      • 16.3.2. Delivery Technology
      • 16.3.3. Dosage Form
      • 16.3.4. Therapeutic Area
      • 16.3.5. Indication
      • 16.3.6. End User
      • 16.3.7. Country
        • 16.3.7.1. Turkey
        • 16.3.7.2. UAE
        • 16.3.7.3. Saudi Arabia
        • 16.3.7.4. Israel
        • 16.3.7.5. Rest of Middle East
    • 16.4. Turkey Oral Biologics Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Molecule Type
      • 16.4.3. Delivery Technology
      • 16.4.4. Dosage Form
      • 16.4.5. Therapeutic Area
      • 16.4.6. Indication
      • 16.4.7. End User
    • 16.5. UAE Oral Biologics Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Molecule Type
      • 16.5.3. Delivery Technology
      • 16.5.4. Dosage Form
      • 16.5.5. Therapeutic Area
      • 16.5.6. Indication
      • 16.5.7. End User
    • 16.6. Saudi Arabia Oral Biologics Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Molecule Type
      • 16.6.3. Delivery Technology
      • 16.6.4. Dosage Form
      • 16.6.5. Therapeutic Area
      • 16.6.6. Indication
      • 16.6.7. End User
    • 16.7. Israel Oral Biologics Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Molecule Type
      • 16.7.3. Delivery Technology
      • 16.7.4. Dosage Form
      • 16.7.5. Therapeutic Area
      • 16.7.6. Indication
      • 16.7.7. End User
    • 16.8. Rest of Middle East Oral Biologics Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Molecule Type
      • 16.8.3. Delivery Technology
      • 16.8.4. Dosage Form
      • 16.8.5. Therapeutic Area
      • 16.8.6. Indication
      • 16.8.7. End User
  • 17. Africa Oral Biologics Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Africa Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Molecule Type
      • 17.3.2. Delivery Technology
      • 17.3.3. Dosage Form
      • 17.3.4. Therapeutic Area
      • 17.3.5. Indication
      • 17.3.6. End User
      • 17.3.7. Country
        • 17.3.7.1. South Africa
        • 17.3.7.2. Egypt
        • 17.3.7.3. Nigeria
        • 17.3.7.4. Algeria
        • 17.3.7.5. Rest of Africa
    • 17.4. South Africa Oral Biologics Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Molecule Type
      • 17.4.3. Delivery Technology
      • 17.4.4. Dosage Form
      • 17.4.5. Therapeutic Area
      • 17.4.6. Indication
      • 17.4.7. End User
    • 17.5. Egypt Oral Biologics Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Molecule Type
      • 17.5.3. Delivery Technology
      • 17.5.4. Dosage Form
      • 17.5.5. Therapeutic Area
      • 17.5.6. Indication
      • 17.5.7. End User
    • 17.6. Nigeria Oral Biologics Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Molecule Type
      • 17.6.3. Delivery Technology
      • 17.6.4. Dosage Form
      • 17.6.5. Therapeutic Area
      • 17.6.6. Indication
      • 17.6.7. End User
    • 17.7. Algeria Oral Biologics Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Molecule Type
      • 17.7.3. Delivery Technology
      • 17.7.4. Dosage Form
      • 17.7.5. Therapeutic Area
      • 17.7.6. Indication
      • 17.7.7. End User
    • 17.8. Rest of Africa Oral Biologics Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Molecule Type
      • 17.8.3. Delivery Technology
      • 17.8.4. Dosage Form
      • 17.8.5. Therapeutic Area
      • 17.8.6. Indication
      • 17.8.7. End User
  • 18. South America Oral Biologics Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. South America Oral Biologics Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Molecule Type
      • 18.3.2. Delivery Technology
      • 18.3.3. Dosage Form
      • 18.3.4. Therapeutic Area
      • 18.3.5. Indication
      • 18.3.6. End User
      • 18.3.7. Country
        • 18.3.7.1. Brazil
        • 18.3.7.2. Argentina
        • 18.3.7.3. Rest of South America
    • 18.4. Brazil Oral Biologics Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Molecule Type
      • 18.4.3. Delivery Technology
      • 18.4.4. Dosage Form
      • 18.4.5. Therapeutic Area
      • 18.4.6. Indication
      • 18.4.7. End User
    • 18.5. Argentina Oral Biologics Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Molecule Type
      • 18.5.3. Delivery Technology
      • 18.5.4. Dosage Form
      • 18.5.5. Therapeutic Area
      • 18.5.6. Indication
      • 18.5.7. End User
    • 18.6. Rest of South America Oral Biologics Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Molecule Type
      • 18.6.3. Delivery Technology
      • 18.6.4. Dosage Form
      • 18.6.5. Therapeutic Area
      • 18.6.6. Indication
      • 18.6.7. End User
  • 19. Key Players/ Company Profile
    • 19.1. AstraZeneca plc
      • 19.1.1. Company Details/ Overview
      • 19.1.2. Company Financials
      • 19.1.3. Key Customers and Competitors
      • 19.1.4. Business/ Industry Portfolio
      • 19.1.5. Product Portfolio/ Specification Details
      • 19.1.6. Pricing Data
      • 19.1.7. Strategic Overview
      • 19.1.8. Recent Developments
    • 19.2. Biocon Limited
    • 19.3. Chugai Pharmaceutical
    • 19.4. Cyclo Therapeutics, Inc.
    • 19.5. Diasome Pharmaceuticals, Inc.
    • 19.6. Eli Lilly and Company
    • 19.7. Entera Bio Ltd.
    • 19.8. Innovent Biologics, Inc.
    • 19.9. Merck & Co.
    • 19.10. Novo Nordisk
    • 19.11. Oramed Pharmaceuticals
    • 19.12. Pfizer Inc.
    • 19.13. Protagonist Therapeutics Inc.
    • 19.14. Rani Therapeutics Holdings, Inc.
    • 19.15. Sanofi S.A.
    • 19.16. Sun Pharmaceutical Industries
    • 19.17. Others

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation